Marketing approval of mogamulizumab
Open Access
- 1 July 2012
- journal article
- Published by Informa UK Limited in mAbs
- Vol. 4 (4), 419-425
- https://doi.org/10.4161/mabs.20996
Abstract
Therapeutic properties of antibodies strongly depend on the composition of their glycans. Most of the currently approved antibodies are produced in mammalian cell lines, which yield mixtures of different glycoforms that are close to those of humans, but not fully identical. Glyco-engineering is being developed as a method to control the composition of carbohydrates and to enhance the pharmacological properties of mAbs. The recent approval in Japan of mogamulizumab (POTELIGEO®), the first glyco-engineered antibody to reach the market, is a landmark in the field of therapeutic antibodies. Mogamulizumab is a humanized mAb derived from Kyowa Hakko Kirin’s POTELLIGENT® technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. The approval was granted April 30, 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma.Keywords
This publication has 33 references indexed in Scilit:
- Marketed therapeutic antibodies compendiummAbs, 2012
- An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximabMolecular Immunology, 2012
- An innovative approach for the characterization of the isoforms of a monoclonal antibody productmAbs, 2011
- Glycoprotein production in moss bioreactorsPlant Cell Reports, 2011
- High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humansGlycobiology, 2011
- Assessing monoclonal antibody product quality attribute criticality through clinical studiesmAbs, 2010
- EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activitymAbs, 2010
- Strategies and challenges for the next generation of therapeutic antibodiesNature Reviews Immunology, 2010
- Evolution of anti- CD20 monoclonal antibody therapeutics in oncologymAbs, 2010
- Production of therapeutic antibodies with controlled fucosylationmAbs, 2009